Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1899 1
1901 1
1902 1
1903 4
1905 1
1906 2
1907 1
1912 1
1914 1
1915 1
1916 1
1919 1
1920 1
1921 1
1925 1
1927 1
1928 1
1929 1
1932 1
1934 1
1937 1
1964 1
1971 1
1974 2
1975 1
1976 1
1977 1
1979 2
1981 2
1982 1
1983 1
1984 1
1986 1
1992 2
1993 1
1994 1
1995 1
1996 3
1998 2
1999 3
2000 2
2001 3
2002 3
2004 4
2005 3
2006 4
2007 10
2008 11
2009 16
2010 13
2011 10
2012 6
2013 3
2014 13
2015 15
2016 14
2017 24
2018 22
2019 27
2020 29
2021 44
2022 37
2023 68
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

402 results

Results by year

Filters applied: . Clear all
Page 1
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ, Jayne DRW, Jha V, Liew A, Liu ZH, Mejía-Vilet JM, Nester CM, Radhakrishnan J, Rave EM, Reich HN, Ronco P, Sanders JF, Sethi S, Suzuki Y, Tang SCW, Tesar V, Vivarelli M, Wetzels JFM, Lytvyn L, Craig JC, Tunnicliffe DJ, Howell M, Tonelli MA, Cheung M, Earley A, Floege J. Rovin BH, et al. Among authors: barratt j. Kidney Int. 2021 Oct;100(4):753-779. doi: 10.1016/j.kint.2021.05.015. Kidney Int. 2021. PMID: 34556300 Free article.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Among authors: barratt j. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Long-Term Outcomes in IgA Nephropathy.
Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA, Steenkamp R, Wong K, Turner AN, Wang K, Gale DP, Barratt J. Pitcher D, et al. Among authors: barratt j. Clin J Am Soc Nephrol. 2023 Jun 1;18(6):727-738. doi: 10.2215/CJN.0000000000000135. Epub 2023 Apr 13. Clin J Am Soc Nephrol. 2023. PMID: 37055195
IgA nephropathy.
Stamellou E, Seikrit C, Tang SCW, Boor P, Tesař V, Floege J, Barratt J, Kramann R. Stamellou E, et al. Among authors: barratt j. Nat Rev Dis Primers. 2023 Nov 30;9(1):67. doi: 10.1038/s41572-023-00476-9. Nat Rev Dis Primers. 2023. PMID: 38036542 Review.
IgA nephropathy in adults-treatment standard.
Gleeson PJ, O'Shaughnessy MM, Barratt J. Gleeson PJ, et al. Among authors: barratt j. Nephrol Dial Transplant. 2023 Oct 31;38(11):2464-2473. doi: 10.1093/ndt/gfad146. Nephrol Dial Transplant. 2023. PMID: 37418237 Free PMC article. Review.
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Barratt J, et al. Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. Kidney Int. 2023. PMID: 36270561 Free article. Clinical Trial.
Glomerular diseases in pregnancy: pragmatic recommendations for clinical management.
Fakhouri F, Schwotzer N, Cabiddu G, Barratt J, Legardeur H, Garovic V, Orozco-Guillen A, Wetzels J, Daugas E, Moroni G, Noris M, Audard V, Praga M, Llurba E, Wuerzner G, Attini R, Desseauve D, Zakharova E, Luders C, Wiles K, Leone F, Jesudason S, Costedoat-Chalumeau N, Kattah A, Soto-Abraham V, Karras A, Prakash J, Lightstone L, Ronco P, Ponticelli C, Appel G, Remuzzi G, Tsatsaris V, Piccoli GB. Fakhouri F, et al. Among authors: barratt j. Kidney Int. 2023 Feb;103(2):264-281. doi: 10.1016/j.kint.2022.10.029. Epub 2022 Dec 5. Kidney Int. 2023. PMID: 36481180 Review.
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lafayette R, Kristensen J, Stone A, Floege J, Tesař V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J; NefIgArd trial investigators. Lafayette R, et al. Among authors: barratt j. Lancet. 2023 Sep 9;402(10405):859-870. doi: 10.1016/S0140-6736(23)01554-4. Epub 2023 Aug 14. Lancet. 2023. PMID: 37591292 Clinical Trial.
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.
Mathur M, Barratt J, Chacko B, Chan TM, Kooienga L, Oh KH, Sahay M, Suzuki Y, Wong MG, Yarbrough J, Xia J, Pereira BJG; ENVISION Trial Investigators Group. Mathur M, et al. Among authors: barratt j. N Engl J Med. 2024 Jan 4;390(1):20-31. doi: 10.1056/NEJMoa2305635. Epub 2023 Nov 2. N Engl J Med. 2024. PMID: 37916620 Clinical Trial.
Next-Generation Morphometry for pathomics-data mining in histopathology.
Hölscher DL, Bouteldja N, Joodaki M, Russo ML, Lan YC, Sadr AV, Cheng M, Tesar V, Stillfried SV, Klinkhammer BM, Barratt J, Floege J, Roberts ISD, Coppo R, Costa IG, Bülow RD, Boor P. Hölscher DL, et al. Among authors: barratt j. Nat Commun. 2023 Jan 28;14(1):470. doi: 10.1038/s41467-023-36173-0. Nat Commun. 2023. PMID: 36709324 Free PMC article.
402 results